About Jeffrey A. Lindeman, Ph.D., Esq.
Jeff Lindeman founded J.A. Lindeman & Co. PLLC on December 1, 2009.
Jeff has over 30 years of intellectual property law experience. Jeff works with clients, large and small companies and universities, in all areas of technology to develop a strategic intellectual property portfolio that provides meaningful protection for their business, in the U.S. and internationally.
Jeff’s personal practice focuses on the chemical and pharmaceutical industries, with areas of emphasis in fine chemicals, catalysts and reagents, in polymers and in the solid-state forms of pharmaceuticals, e.g., polymorphs, co-crystals and amorphous forms.
Prior to founding the firm, Jeff practiced with firms in the Washington, DC area and in Knoxville, TN focusing on patent law and intellectual property. Jeff was a partner at Morgan, Lewis and Bockius and at Nixon Peabody where he was the firm’s patent practice group leader. Jeff has been adjunct professor at American University’s Washington College of Law teaching classes on US and international patent law. He is a former United States patent examiner and worked as a detailee in the USPTO Office of Legislation and International Affairs.
Education & Honors
- West Virginia University, B.A. Chemistry
- University of South Carolina, Ph.D. Chemistry
- Georgetown University Law Center, J.D. Cum Laude
- District of Columbia
- Registered to practice before the U.S. Patent and Trademark Office
Publications & Presentations
Jeff is a frequent speaker and has published articles and book chapters on US patent law. These include the following:
Lindeman, J.A., “PATENTING AMORPHOUS SOLID DISPERSIONS OF PHARMACEUTICALS”, Pharmaceutical Amorphous Solid Dispersions, edited by Ann Newman, Wiley, Ch. 13, 2015.
Lindeman, J.A., Parisi, J. A., “DRAFTING THE PATENT APPLICATION”, Introduction to Patentability in Drug Development, ebook, 2016, https://doi.org/10.4155/9781910419533.
Hoffman, M., Lindeman, J.A.; “CO-CRYSTALS: COMMERCIAL AND PATENT CONSIDERATIONS”, RSC Drug Discovery Series No. 16, Pharmaceutical Salts and Co-Crystals, Ch. 14, 2012.
Lindeman, J.A., “PATENTS AND THE US FDA’S DEFINITION OF ‘COCRYSTAL’: AN ORDINARY AND CUSTOMARY MEANING?”, Pharmaceutical Patent Analyst, Nov. 2012, Vol. 1, No. 5, pgs. 513-15.